Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
European Archives of Oto-Rhino-Laryngology · 2023
DOI: 10.1007/s00405-023-08085-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2023. Verfasst von Arianna Di Stadio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology Unit, GF Ingrassia Department, University of Catania, Catania, Italy. ariannadistadio@hotmail.com. Hauptthemen laut MEDLINE: COVID-19, Olfaction Disorders. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Catania.
Abstract (Originalsprache)
Purpose
Few evidence-based therapies are available for chronic olfactory dysfunction after COVID-19. This study investigated the relative efficacy of olfactory training alone, co-ultramicronized palmitoylethanolamide with luteolin (um-PEA–LUT, an anti-neuroinflammatory supplement) alone, or combined therapy for treating chronic olfactory dysfunction from COVID-19.
Methods
This double-blinded controlled, placebo-controlled multicenter randomized clinical trial was conducted in 202 patients with persistent COVID-19 olfactory dysfunction of > 6 month duration. After a screening nasal endoscopy, patients were randomized to: (1) olfactory training and placebo; (2) once daily um-PEA–LUT alone; (3) twice daily um-PEA–LUT alone; or (4) combination of once daily um-PEA–LUT with olfactory training. Olfactory testing (Sniffin’ Sticks odor identification test) was performed at baseline and at 1, 2, and 3 months. The primary outcome was recovery of over three points on olfactory testing, with outcomes compared at T 0 , T 1 , T 2 and T 3 across groups. Statistical analyses included one-way ANOVA for numeric data and chi-square for nominal data.
Results
All patients completed the study, and there were no adverse events. At 90 days, odor identification scores improved by > 3 points in 89.2% of patients receiving combined therapy vs. 36.8% receiving olfactory training with placebo, 40% receiving twice daily um-PEA–LUT alone, and 41.6% receiving once daily um-PEA–LUT alone ( p < 0.00001). Patients receiving treatment with um-PEA–LUT alone demonstrated subclinical improvement (< 3 point odor identification improvement) more often than patients receiving olfactory training with placebo ( p < 0.0001.)
Conclusions
Olfactory training plus once daily um-PEA–LUT resulted in greater olfactory recovery than either therapy alone in patients with long-term olfactory function due to COVID-19.
Trial registration
20112020PGFN on clinicaltrials.gov. Level of evidence 1b (Individual Randomized Clinical Trial).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otolaryngology Unit, GF Ingrassia Department, University of Catania, Catania, Italy. ariannadistadio@hotmail.com.
- Otolaryngology Department, University of Palermo, Palermo, Italy.
- Otolaryngology Unit, GF Ingrassia Department, University of Catania, Catania, Italy.
- Otolaryngology Department, San Giovanni-Addolorata Hospital, Rome, Italy.
- Otolaryngology Department, Humanitas University Hospital, Milan, Italy.
- Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Förderung
- Università degli Studi di Catania
Zitieren
APA
Di Stadio, A., Gallina, S., Cocuzza, S., De Luca, P., Ingrassia, A., Oliva, S., Sireci, F., Camaioni, A., Ferreli, F., Mercante, G., Gaino, F., Pace, G. M., La Mantia, I., & Brenner, M. J. (2023). Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-023-08085-8
Vancouver
Di Stadio A, Gallina S, Cocuzza S, De Luca P, Ingrassia A, Oliva S, et al. Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial. European Archives of Oto-Rhino-Laryngology. 2023. doi:10.1007/s00405-023-08085-8
BibTeX
@article{DiStadio2023,
author = {Di Stadio, Arianna and Gallina, Salvatore and Cocuzza, Salvatore and De Luca, Pietro and Ingrassia, Angelo and Oliva, Simone and Sireci, Federico and Camaioni, Angelo and Ferreli, Fabio and Mercante, Giuseppe and Gaino, Francesca and Pace, Gian Marco and La Mantia, Ignazio and Brenner, Michael J},
title = {Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2023},
doi = {10.1007/s00405-023-08085-8}
}
EUVIMED